A safe pain reliever? New research raises concerns about the safety of Tilanol during pregnancy

Acetaminophen (often sold under the Tylenol® brand, known as paracetamol outside the United States and Canada) is more commonly used and fever during pregnancy and is used by more than half of pregnant women all over the world. To date, acetaminophen is the safest option for headache management, fever and other pain. The analysis conducted by the Mount Sinai team led by 46 studies that include data from more than 100,000 participants across many countries challenge this perception and confirms the need for both caution and further study.

The systematic review methodology of the transportation guide is a golden framework for the collection and evaluation of environmental health data. This approach allows researchers to evaluate and evaluate the risk of each study of bias, such as selective reporting of incomplete results or data, as well as the strength of evidence and the quality of studies individually.

“The results we have found shows that high -quality studies are likely to show a link between exposure to prenatitis, increasing the risk of autism, hyperactivity disorder,” said Dodier Prada, a doctorate in medicine at Ekan School at Mount Sinai. “Given the wide use of this drug, even a slight increase in risk can have significant impacts on public health.”

The paper also explores the biological mechanisms that can explain the relationship between the use of acetaminophen and these disorders. It is known that acetaminophen crosses the placenta barrier and may lead to oxidative stress, disrupt hormones, and causes genetic changes that interfere with the development of the brain of the fetus.

While the study does not show that acetaminophen directly causes nervous growth disorders, the results of the research team enhance the existence of communication and increase concerns about current clinical practices.

Researchers call for cautious and limited use of time for iyaminophen during pregnancy under medical supervision; Update clinical instructions to improve the balance between benefits and risks; More research to confirm these results and determine the safest alternatives to pain and fever management in pregnant mothers.

“Pregnant women should not stop taking the medicine without consulting their doctors,” Dr. Brada stressed. “Increased pain or fever can also harm the child. Our study highlights the importance of discussing the safest approach with health care providers and considering non -drug options whenever possible.”

With an increase in autism, hyperactivity disorder, lack of attention around the world, these results have significant effects on public health policy, clinical guidelines, and patient education. The study also highlights the urgent need for pharmaceutical innovation to provide safer alternatives to pregnant women.

The study was conducted in cooperation with the University of California, Los Angeles; Massachusetts University Lowl; Harvard Chan Public Health School.

Funding for this study was provided by the National Cancer Institute (U54CA267776), the National Institute of Environmental Health Sciences (R35es031688), and the National Institute of Agency (U01ag088684).